RESUMO
Optimal dosage for chemotherapy administered to patients on chronic hemodialysis remains a difficult question. We report the case of a patient with chronic renal failure on hemodialysis for 9 years who was treated for small-cell lung cancer. The chemotherapy protocol combined carboplatin and etoposide at doses adapted to creatinine clearance. Tumor regression was observed after 6 cycles without major intolerance.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Carcinoma Broncogênico/tratamento farmacológico , Carcinoma de Células Pequenas/tratamento farmacológico , Falência Renal Crônica/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Diálise Renal , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carboplatina/administração & dosagem , Carboplatina/efeitos adversos , Carcinoma Broncogênico/complicações , Carcinoma de Células Pequenas/complicações , Relação Dose-Resposta a Droga , Esquema de Medicação , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Humanos , Falência Renal Crônica/complicações , Neoplasias Pulmonares/complicações , Masculino , Pessoa de Meia-IdadeRESUMO
A competitive indirect ELISA is described for the measurement of IgG4 levels. It uses a monoclonal anti-subclass and antibody and purified monoclonal IgG4 as standards. This method is sensitive and reproducible and more accurate than hemagglutination inhibition and radial immunodiffusion. Serum IgG4 levels in 173 normal adults were less than 0.01-2.1 mg/ml (mean 0.30 mg/ml) in women and less than 0.01-1.87 mg/ml (mean 0.465 mg/ml) in men.